Shares of Prima BioMed Ltd (NASDAQ:IMMP – Get Free Report) have been given an average rating of “Hold” by the five research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $110.00.
Several equities research analysts recently commented on the stock. Jefferies Financial Group upgraded shares of Prima BioMed from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Prima BioMed in a research report on Tuesday, October 6th.
Read Our Latest Analysis on Prima BioMed
Prima BioMed Stock Up 2.5%
Shares of IMMP opened at $3.65 on Friday. The firm’s 50 day moving average is $4.48 and its 200-day moving average is $14.93. Prima BioMed has a 12-month low of $2.66 and a 12-month high of $70.60.
Prima BioMed (NASDAQ:IMMP – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($1.80) earnings per share for the quarter. The company had revenue of $3.68 million during the quarter.
About Prima BioMed
Prima BioMed Limited was an Australian biotechnology company focused on developing immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the body’s immune response against tumors. Its principal product candidate was IMP321, also known as eftilagimod alpha, a soluble LAG-3 protein intended to stimulate antigen-presenting cells and support T-cell activity. Prima BioMed evaluated the therapy in combination with other cancer treatments, including chemotherapy and immune checkpoint inhibitors, across several solid-tumor indications.
See Also
- Five stocks we like better than Prima BioMed
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Prima BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
